The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
PC3 is a cell line characteristic of prostatic small cell carcinoma
Abstract
BACKGROUND: The majority of the prostatic cancers are adenocarcinomas characterized by glandular formation and the expression of luminal differentiation markers androgen receptor (AR) and prostate‐specific antigen (PSA). Most adenocarcinomas are indolent and androgen‐dependent. Hormonal therapy that inhibits AR signaling produces symptomatic relief in patients with advanced and metastatic adenocarcinomas. Prostatic small cell neuroendocrine carcinoma (SCNC) is a variant form of prostate cancer (PC). In contrast to adenocarcinoma, the tumor cells of SCNC do not form glands and are negative for AR and PSA. SCNC is extremely aggressive and does not respond to hormonal therapy. The purpose of this study was to compare the important and relevant features of two most commonly used PC cell lines, LNCaP and PC3, with prostatic adenocarcinoma and SCNC. METHODS: Xenograft tumors of LNCaP and PC3 were prepared and compared with human prostatic adenocarcinoma and SCNC for the expression of key signaling molecules by immunohistochemistry and Western blot analysis. RESULTS: LNCaP cells express AR and PSA and their growth is inhibited by androgen withdrawal, similar to human prostatic adenocarcinoma. PC3 cells do not express AR and PSA and their proliferation is independent of androgen, similar to SCNC. Adenocarcinoma cells and LNCaP cells are negative for neuroendocrine markers and stem cell‐associated marker CD44 while SCNC and PC3 cells are positive. LNCaP cells have identical cytokeratin profiles to adenocarcinoma while PC3 cells have cytokeratin profiles similar to SCNC. CONCLUSION: LNCaP cells share common features with adenocarcinoma while PC3 cells are characteristic of SCNC. Prostate 71:1668–1679, 2011. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In terms of metastatic potential, PC3 cells are thought to be the most aggressive, with LNCaP being relatively more quiescent and DU145 somewhere in between (45, 46).”
From FACS-assisted single-cell lipidome analysis of phosphatidylcholines and sphingomyelins in cells of different lineages (2023) · doi:10.1016/j.jlr.2023.100341 · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 1,603
Patrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J. G., Chandra, D., Zhou, J., Claypool, K., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209327 · Cited by 968
Fine, H. A., Dear, K. B. G., Loeffler, J. S., Black, P. M., & Canellos, G. P. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2574::aid-cncr2820710823>3.0.co;2-1 · Cited by 861
A luminal epithelial stem cell that is a cell of origin for prostate cancer
Wang, X., Julio, M. K.-D., Economides, K. D., Walker, D., Yu, H., Halili, M. V., Hu, Y.-P., Price, S. M., Abate-Shen, C., & Shen, M. M. (2009) · Nature · doi:10.1038/nature08361 · Cited by 734
Molecular characterization of human prostate carcinoma cell lines
van Bokhoven, A., Varella‐Garcia, M., Korch, C., Johannes, W. U., Smith, E. E., Miller, H. L., Nordeen, S. K., Miller, G. J., & Lucia, M. S. (2003) · The Prostate · doi:10.1002/pros.10290 · Cited by 633
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Identification of a Cell of Origin for Human Prostate Cancer
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010) · Science · doi:10.1126/science.1189992 · Cited by 554
Self-citationThe LNCaP cell line--a new model for studies on human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z., Friedman, M., Papsidero, L. D., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., et al. (1980) · PubMed · Cited by 544
Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases
Wang, W., & Epstein, J. I. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318058a96b · Cited by 375
Tanaka, H., Kono, E., Tran, C. P., Miyazaki, H., Yamashiro, J., Shimomura, T., Fazli, L., Wada, R., Huang, J., Vessella, R. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2236 · Cited by 339
Self-citationCell differentiation lineage in the prostate
Wang, Y., Hayward, S. W., Cao, M., Thayer, K. A., & Cunha, G. R. (2001) · Differentiation · doi:10.1046/j.1432-0436.2001.680414.x · Cited by 304
Papandreou, C. N., Daliani, D. D., Thall, P. F., Tu, S.-M., Wang, X., Reyes, A., Troncoso, P., & Logothetis, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.065 · Cited by 286
Small cell carcinoma of the prostate part I a clinicopathologic study of 20 cases
Tětu, B., Ro, J. Y., Ayala, A. G., Johnson, D. E., Logothetis, C. J., & Ordonez, N. G. (1987) · Cancer · doi:10.1002/1097-0142(19870515)59:10<1803::aid-cncr2820591019>3.0.co;2-x · Cited by 278
Basal epithelial stem cells are efficient targets for prostate cancer initiation
Lawson, D. A., Zong, Y., Memarzadeh, S., Xin, L., Huang, J., & Witte, O. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913873107 · Cited by 275
Self-citationNeuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
Vashchenko, N., & Abrahamsson, P.-A. (2005) · European Urology · doi:10.1016/j.eururo.2004.09.007 · Cited by 260
Borgström, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., & Ferrara, N. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980401)35:1<63::aid-pros9>3.0.co;2-i · Cited by 247
Yuan, T.-C., Veeramani, S., & Lin, M.-F. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0061 · Cited by 231
Small Cell Carcinoma of the Prostate: An Immunohistochemical Study
Yao, J. L., Madeb, R., Bourne, P., Lei, J., Yang, X., Tickoo, S., Liu, Z., Tan, D., Cheng, L., Hatem, F., et al. (2006) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200606000-00005 · Cited by 206
Self-citationCD44 and EpCAM: Cancer-Initiating Cell Markers
Marhaba, R., Klingbeil, P., Nuebel, T., Nazarenko, I., Buechler, M., & Zoeller, M. (2008) · Current Molecular Medicine · doi:10.2174/156652408786733667 · Cited by 192
Oesterling, J. E., Hauzeur, C. G., & Farrow, G. M. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37390-1 · Cited by 192
Mulholland, D. J., Xin, L., Morim, A., Lawson, D., Witte, O., & Wu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4673 · Cited by 179
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells
Uysal-Onganer, P., Kawano, Y., Caro, M., Walker, M. M., Diez, S., Darrington, R. S., Waxman, J., & Kypta, R. M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-55 · Cited by 171
BURCHARDT, T., BURCHARDT, M., CHEN, M.-W., CAO, Y., DE LA TAILLE, A., SHABSIGH, A., HAYEK, O., DORAI, T., & BUTTYAN, R. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68241-9 · Cited by 170
Contribution of the Androgen Receptor to Prostate Cancer Predisposition and Progression
Buchanan, G., Irvine, R. A., Coetzee, G. A., & Tilley, W. D. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1015531326689 · Cited by 165
Unusual subtypes of prostate cancer
Grignon, D. J. (2004) · Modern Pathology · doi:10.1038/modpathol.3800052 · Cited by 165
Chemotherapy for Small Cell Carcinoma of Prostatic Origin
Amato, R. J., Logothetis, C. J., Hallinan, R., Ro, J. Y., Sella, A., & Dexeus, F. H. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37427-x · Cited by 164
Neuroendocrine Differentiation in Prostatic Carcinoma During Hormonal Treatment
Jiborn, T., Bjartell, A., & Abrahamsson, P.-A. (1998) · Urology · doi:10.1016/s0090-4295(97)00684-5 · Cited by 149
Bonkhoff, H. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s141 · Cited by 145
Neuroendocrine differentiation in prostate cancer
Kirby, R. S., Partin, A. W., Feneley, M. R., & Parsons, J. K. (2005) · Prostate Cancer · doi:10.1201/b14450-17 · Cited by 144
Immunohistochemical characterization of neuroendocrine cells in prostate cancer
Huang, J., Yao, J. L., di Sant'Agnese, P. A., Yang, Q., Bourne, P. A., & Na, Y.-Q. (2006) · The Prostate · doi:10.1002/pros.20434 · Cited by 121
Self-citationPalapattu, G. S., Wu, C., Silvers, C. R., Martin, H. B., Williams, K., Salamone, L., Bushnell, T. P., Huang, L., Yang, Q., & Huang, J. (2009) · The Prostate · doi:10.1002/pros.20928 · Cited by 120
Self-citationHuang, J., Yao, J. L., Zhang, L., Bourne, P. A., Quinn, A. M., di Sant'Agnese, P. A., & Reeder, J. E. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62490-x · Cited by 112
Self-citationNeuroendocrine differentiation in prostate cancer
Wang, J., & Yao, Y. (2008) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-007-0184-3 · Cited by 93
Progression of prostate cancer to neuroendocrine cell tumor
Tanaka, M., Suzuki, Y., Takaoka, K., Suzuki, N., Murakami, S., Matsuzaki, O., & Shimazaki, J. (2001) · International Journal of Urology · doi:10.1046/j.1442-2042.2001.00347.x · Cited by 93
Simon, R. A., di Sant'Agnese, P. A., Huang, L., Xu, H., Yao, J. L., Yang, Q., Liang, S. X., Liu, J., Yu, R., Cheng, L., et al. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.07.014 · Cited by 73
Self-citationYang, Y.-M., Hao, J., Liu, X., Dalkin, B. L., & Nagle, R. B. (1997) · PubMed · Cited by 59
Marchiani, S., Tamburrino, L., Nesi, G., Paglierani, M., Gelmini, S., Orlando, C., Maggi, M., Forti, G., & Baldi, E. (2010) · International Journal of Andrology · doi:10.1111/j.1365-2605.2009.01030.x · Cited by 58
Pertschuk, L. P., Schaeffer, H., Feldman, J. G., Macchia, R. J., Kim, Y. D., Eisenberg, K. B., Braithwaite, L., Axiotis, C. A., Prins, G. S., & Green, G. L. (1995) · PubMed · Cited by 58
Miyoshi, Y., Uemura, H., Kitami, K., Satomi, Y., Kubota, Y., & Hosaka, M. (2001) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.00936.x · Cited by 57
Ahlegren, G., Pedersen, K., Lundberg, S., Aus, G., Hugosson, J., & Abrahamsson, P. (2000) · Urology · doi:10.1016/s0090-4295(00)00838-4 · Cited by 47
Function and molecular mechanisms of neuroendocrine cells in prostate cancer.
Huang, J., Wu, C., di Sant'Agnese, P. A., Yao, J. L., Cheng, L., & Na, Y.-Q. (2007) · PubMed · Cited by 46
Self-citationProstate cancer 2004: insights from national disease registries.
Cooperberg, M. R., Park, S., & Carroll, P. R. (2004) · PubMed · Cited by 43
Zhang, C., Soori, M. M., Miles, F. L., Sikes, R. A., Carson, D. D., Chung, L. W. K., & Farach‐Carson, M. C. (2010) · The Prostate · doi:10.1002/pros.21231 · Cited by 33
New agents and strategies for the hormonal treatment of castration-resistant prostate cancer
Sharifi, N. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.494178 · Cited by 32
Prostate cancer with small-cell morphology: An immunophenotypic subdivision
Petraki, C. D., Vaslamatzis, M. M., Petraki, K., Revelos, K., Alevizopoulos, N., Papanastasiou, P., & Gregorakis, A. (2005) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590500199855 · Cited by 14
Cited by
Selective Targeting of Cancer Cells by Copper Ionophores: An Overview
Oliveri, V. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.841814 · Cited by 367
Fahey, J. M., & Girotti, A. W. (2015) · Nitric Oxide · doi:10.1016/j.niox.2015.05.006 · Cited by 77
Lu, T.-L., Han, C.-K., Chang, Y.-S., Lu, T.-J., Huang, H.-C., Bao, B.-Y., Wu, H.-Y., Huang, C.-H., Li, C.-Y., & Wu, T.-S. (2014) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x14500967 · Cited by 37
Okada, T., Uto, K., Aoyagi, T., & Ebara, M. (2016) · Biomaterials Science · doi:10.1039/c5bm00375j · Cited by 20
Hancock, S. E., Ding, E., Johansson Beves, E., Mitchell, T., & Turner, N. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100341 · Cited by 13
Metadata
- Authors
- Tai, S., Sun, Y., Squires, J. M., Zhang, H., Oh, W. K., Liang, C., & Huang, J.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2011-03-22
- Volume
- 71
- Issue
- 15
- Pages
- 1668-1679
- ISSN
- 0270-4137
- 1097-0045
- PMC
- PMC3426349
- Cited by
- 438
- References
- 46
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.